The Medicines and Healthcare products Regulatory Agency (MHRA) is inviting feedback on plans to end use of the European Commission Decision Reliance Procedure (ECDRP) to bring medicines to market.
The UK Medicines and Healthcare products Regulatory Agency’s (MHRA) annual report and accounts for 2022-2023 was printed on 19 July 2023. The report outlines achievements during the year, such as its evolution into a ‘One Agency’ organisation, uniting its regulatory, research and standards and clinical data service.
A High Court judgment on a judicial review brought by the British Generic Manufacturers Association (BGMA) has dismissed the organisation’s claim that it was unfairly excluded from talks on the next Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has published its corporate plan for the next three years, featuring a focus on patient access to innovation.
Four important themes for the life sciences were the focus of the Professional Industry Network Group (PING) conference, held in June 2023. These included the position of the Medicines and Healthcare products Regulatory Agency (MHRA) post the COVID-19 pandemic, the implications of the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) and the proposed Voluntary Scheme for Pricing, Access and Growth (VPAG), plus whether there were adequate staffing and premises to support the sector.
The leaders of the European Federation of Pharmaceutical Industries and Associations (EFPIA) have warned that the proposed reforms to the European Commission’s (EC) Pharmaceutical Legislation should be revised as they believe they risk damaging Europe’s capacity for innovation and international competitiveness.
The much anticipated O’Shaughnessy report examining commercial clinical trials in the UK was published at the end of May 2023. Its findings have prompted the UK government to initiate a series of actions, in response to its 27 recommendations, that are designed to make the UK a world leader in this important part of the life sciences industry.
The new report, ‘Promoting population health through pharmaceutical policy: The role of the UK Voluntary Scheme’, produced by researchers at the London School of Economics, London School of Hygiene & Tropical Medicine (LSHTM) and University of York, investigates the costs of prescription medicines to the NHS in England.
The government has announced that new measures laid out in the Windsor Framework regarding the supply of medicines to Northern Ireland will commence from 1 January 2025. This extends the previous deadline for compliance, which was 31 December 2023.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced a new international framework that will help bring new medicines to patients faster.
